LT3893B - Pharmaceutical composition with nalmefene for treating alcoholism - Google Patents

Pharmaceutical composition with nalmefene for treating alcoholism Download PDF

Info

Publication number
LT3893B
LT3893B LTIP1486A LTIP1486A LT3893B LT 3893 B LT3893 B LT 3893B LT IP1486 A LTIP1486 A LT IP1486A LT IP1486 A LTIP1486 A LT IP1486A LT 3893 B LT3893 B LT 3893B
Authority
LT
Lithuania
Prior art keywords
alcohol
nalmefene
patient
treatment
rats
Prior art date
Application number
LTIP1486A
Other languages
English (en)
Lithuanian (lt)
Inventor
John D Sinclair
Harry Scheinin
Risto Arvo Sakari Lammintausta
Original Assignee
Alko Ltd
Orion Corp Farmos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alko Ltd, Orion Corp Farmos filed Critical Alko Ltd
Publication of LTIP1486A publication Critical patent/LTIP1486A/xx
Publication of LT3893B publication Critical patent/LT3893B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
LTIP1486A 1990-06-04 1993-11-25 Pharmaceutical composition with nalmefene for treating alcoholism LT3893B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/532,424 US5086058A (en) 1990-06-04 1990-06-04 Method for treating alcoholism with nalmefene

Publications (2)

Publication Number Publication Date
LTIP1486A LTIP1486A (en) 1995-09-25
LT3893B true LT3893B (en) 1996-04-25

Family

ID=24121726

Family Applications (1)

Application Number Title Priority Date Filing Date
LTIP1486A LT3893B (en) 1990-06-04 1993-11-25 Pharmaceutical composition with nalmefene for treating alcoholism

Country Status (19)

Country Link
US (1) US5086058A (lv)
EP (1) EP0531415B1 (lv)
JP (1) JP3059213B2 (lv)
AT (1) ATE145329T1 (lv)
AU (1) AU642748B2 (lv)
CA (1) CA2084519C (lv)
DE (1) DE69123247T2 (lv)
DK (1) DK0531415T3 (lv)
ES (1) ES2097209T3 (lv)
FI (1) FI925513A0 (lv)
GR (1) GR3022289T3 (lv)
HU (1) HU210637B (lv)
IE (1) IE77333B1 (lv)
LT (1) LT3893B (lv)
LV (1) LV10190B (lv)
NZ (1) NZ238391A (lv)
RU (1) RU2090190C1 (lv)
WO (1) WO1991018605A1 (lv)
ZA (1) ZA914185B (lv)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US6271239B1 (en) * 1992-04-13 2001-08-07 Regents Of The University Of Minnesota Delta opioid receptor-selective benzylidene-substituted morphinans
US5352680A (en) * 1992-07-15 1994-10-04 Regents Of The University Of Minnesota Delta opioid receptor antagonists to block opioid agonist tolerance and dependence
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
USRE36547E (en) * 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US6096756A (en) 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5298622A (en) * 1993-05-12 1994-03-29 Regents Of The University Of Minnesota Spiroindane opiate analogs
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
US5587381A (en) * 1995-03-27 1996-12-24 Sinclair; John D. Method for terminating methadone maintenance through extinction of the opiate-taking responses
WO1997018781A1 (en) * 1995-11-20 1997-05-29 University Of Miami Method of treating nicotine dependence
US5878750A (en) * 1996-11-14 1999-03-09 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
US5780479A (en) * 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
KR100417490B1 (ko) 1997-12-22 2004-02-05 유로-셀티크 소시에떼 아노뉨 오피오이드 제형의 남용을 방지하는 방법
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
PT1685839E (pt) 1997-12-22 2013-07-08 Euro Celtique Sa Forma de dosagem farmacêutica por via oral compreendendo uma combinação de um agonista opióide e de um antagonista opióide
WO2001040269A2 (en) * 1999-11-30 2001-06-07 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
AU776904B2 (en) 2000-02-08 2004-09-23 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US20040024004A1 (en) * 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
US6528520B2 (en) * 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6262062B1 (en) * 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
DE60238756D1 (de) 2001-05-11 2011-02-10 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
US7879211B2 (en) * 2001-07-13 2011-02-01 Arkray, Inc. Analyzing instrument, lancet-integrated attachment for concentration measuring device provided with analyzing instrument, and body fluid sampling tool
WO2003007802A2 (en) * 2001-07-18 2003-01-30 Euro-Celtique, S.A. Pharmaceutical combinations of oxycodone and naloxone
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
JP4504013B2 (ja) 2001-08-06 2010-07-14 ユーロ−セルティーク エス．エイ． 放出可能な及び封鎖されたアンタゴニストを有するオピオイドアゴニスト製剤
AU2002324624A1 (en) * 2001-08-06 2003-02-24 Euro-Celtique S.A. Sequestered antagonist formulations
WO2003015783A1 (en) * 2001-08-14 2003-02-27 Biotie Therapies Corporation Method of treating alcoholism or alcohol abuse
DE20308437U1 (de) 2002-04-05 2003-11-13 Euroceltique S.A., Luxemburg/Luxembourg Matrix zur verzögerten, gleichbleibenden und unabhängigen Freisetzung von Wirkstoffen
US7501433B2 (en) * 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US7923454B2 (en) * 2002-05-17 2011-04-12 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
EP1509182A4 (en) * 2002-05-31 2009-12-30 Titan Pharmaceuticals Inc IMPLANTABLE POLYMERS DEVICE FOR THE DELAYED RELEASE OF BUPRENORPHINE
EP2422775A3 (en) 2002-09-20 2012-04-18 Alpharma, Inc. Sequestering subunit and related compositions and methods
MXPA05010450A (es) 2003-03-31 2005-11-04 Titan Pharmaceuticals Inc Dispositivo polimerico implantable para la liberacion prolongada de agonistas de dopamina.
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
US20050038062A1 (en) * 2003-04-14 2005-02-17 Burns Lindsay H. Methods and materials for the treatment of pain comprising opioid antagonists
MY135852A (en) * 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US8017622B2 (en) * 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US20060009478A1 (en) * 2003-10-15 2006-01-12 Nadav Friedmann Methods for the treatment of back pain
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1702558A1 (en) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
SI2484346T1 (sl) 2006-06-19 2017-05-31 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
CA2666846C (en) * 2006-10-20 2018-04-10 Cpd, Llc Method of restoring the incretin effect
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
AU2008346870A1 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
EP2291380B1 (en) * 2008-04-24 2011-09-07 Janssen Pharmaceutica N.V. Nalmefene prodrugs
US20110053971A1 (en) * 2008-04-24 2011-03-03 Janssen Pharmaceutica Nv Nalmefene di-ester prodrugs
MY150600A (en) * 2008-07-07 2014-01-30 Euro Celtique Sa Use of opioid antagonists for treating urinary retention
PT2405915T (pt) 2009-03-10 2019-01-29 Euro Celtique Sa Composições farmacêuticas de libertação imediata compreendendo oxicodona e naloxona
US20140005217A1 (en) * 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
WO2014170353A1 (en) * 2013-04-17 2014-10-23 H. Lundbeck A/S Nalmefene for treatment of patients with sleep disorder
NZ716267A (en) 2013-07-23 2017-05-26 Euro Celtique Sa A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
TW201625252A (zh) * 2014-04-22 2016-07-16 大塚製藥股份有限公司 藥物
WO2016073615A1 (en) 2014-11-07 2016-05-12 Regents Of The University Of Minnesota Salts and compositions useful for treating disease
AU2017253228B2 (en) * 2016-04-22 2020-04-09 Taiwanj Pharmaceuticals Co., Ltd. Nalmefene, naltrexone or derivatives thereof for use in treating (non)-alcoholic steatohepatitis or non-alcoholic fatty liver disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857533A (en) * 1988-12-15 1989-08-15 Baker Cummins Pharmaceuticals, Inc. Method of treatment for autoimmune diseases
US4863928A (en) * 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
US5096715A (en) * 1989-11-20 1992-03-17 Alko Ltd. Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DIXON AT AL.: "Clin.Pharmacol., Vol.27, 1987", pages: 233 - 239
YEOMANS ET AL.: "Psycopharmacology, vol. 100, 1990", pages: 426 - 432

Also Published As

Publication number Publication date
LTIP1486A (en) 1995-09-25
IE77333B1 (en) 1997-12-03
IE911888A1 (en) 1991-12-04
ZA914185B (en) 1992-07-29
HU9203835D0 (en) 1993-03-29
RU2090190C1 (ru) 1997-09-20
DE69123247T2 (de) 1998-01-15
LV10190A (lv) 1994-10-20
JPH06506665A (ja) 1994-07-28
EP0531415A1 (en) 1993-03-17
WO1991018605A1 (en) 1991-12-12
LV10190B (en) 1995-06-20
FI925513A (fi) 1992-12-04
DK0531415T3 (da) 1996-12-09
US5086058A (en) 1992-02-04
HUT65523A (en) 1994-06-28
ATE145329T1 (de) 1996-12-15
DE69123247D1 (de) 1997-01-02
NZ238391A (en) 1997-06-24
JP3059213B2 (ja) 2000-07-04
GR3022289T3 (en) 1997-04-30
CA2084519A1 (en) 1991-12-05
ES2097209T3 (es) 1997-04-01
EP0531415B1 (en) 1996-11-20
FI925513A0 (fi) 1992-12-04
AU7974091A (en) 1991-12-31
CA2084519C (en) 1999-02-09
AU642748B2 (en) 1993-10-28
HU210637B (en) 1995-06-28

Similar Documents

Publication Publication Date Title
LT3893B (en) Pharmaceutical composition with nalmefene for treating alcoholism
Hoehn-Saric et al. Effects of clonidine on anxiety disorders
Oswald et al. Some experiments in the chemistry of normal sleep
Olson et al. Endogenous opiates: 1997
Papp et al. Toxic effects of iproniazid in a patient with angina
JP2013527132A (ja) 中枢神経系（ｃｎｓ）の自己免疫性脱髄性疾患の治療において使用するためのジアゾキシド
JP2008201796A (ja) アルコール依存症治療用の薬剤
EP1681057A1 (en) Use of naloxone for treating eating disorders
EP0563336A1 (en) Pharmaceutical composition containing gamma-hydroxybutyric acid or its lactone in the treatment of drug dependence and nutritional disorders
KR100425045B1 (ko) 약물중독의치료를위한멜라토닌함유약학적조성물
JP2007529547A (ja) アルコール中毒の処置方法
KR100712571B1 (ko) 코카인 중독증의 치료용 약제를 제조하기 위한플루마제닐의 용도
BG62876B1 (bg) Използване на мелатонин за лечение на пациенти,страдащи от лекарствена зависимост
US6437093B1 (en) Methods of treatment comprising administration of Substance P
Treiman et al. Increasing plasma concentration tolerability study of flunarizine in comedicated epileptic patients
US4861772A (en) Method and composition to treat panic syndrome
WO2017196857A1 (en) Treatment of alcoholism and depression and/or dysphoric mood using ibudilast
Parrott et al. Behaviour of pigs given corticotrophin-releasing hormone in combination with flumazenil or diazepam
Nagain‐Domaine et al. Modulation by alcohol and methadone of 2‐deoxyglucose‐stimulated pancreatic secretion in the rat
Taylor Alcohol and the brain
FR2515044A1 (fr) Composition medicale pour controler le rythme biologique diurne et nocturne de l'organisme humain et plus specifiquement pour combattre les troubles sexuels de l'etre humain

Legal Events

Date Code Title Description
PC9A Transfer of patents

Free format text: CONTRAL CLINICS OY,TAPIOLAN KESKUSTORNI 6KRS, FIN-02100 ESPOO,FI,990910

MK9A Expiry of a patent

Effective date: 20131125